Answers are grounded in this paper and cite their sources.
The risk of complications for transforaminal ESI is greater with particulate corticosteroids. Nonparticulate corticosteroids, which are often recommended as first-line therapy, may have a short duration of effect, and many commercial formulations contain neurotoxic preservatives. The safety profile of ESIs may continue to improve with the development of safer, sterile formulations that reduce the risk of complications while maintaining efficacy.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: